ArticleCell2020
A Dual-Mechanism Antibiotic Kills Gram-Negative Bacteria and Avoids Drug Resistance.
Article in Cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
153 citing papers in PubMed, 2 syntheses or guidelines pooled it, 340 citations in OpenAlex.
- Antimicrobial resistance crisis: could artificial intelligence be the solution?Military Medical Research · 2024Pooled it
- The impact of different antibiotic injection regimens on patients with severe infections: A meta-analysis.International wound journal · 2024Pooled it
- Design, synthesis, and antibacterial activity study of pyrroloquinazoline diamine derivatives.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Predicting resistance evolution to guide antibiotic development.Nature reviews. Microbiology · 2026Review
- [Everolimus inhibits malignant phenotype of erdafitinib-resistant bladder cancer cells through the p70S6K/PI3K/MAPK signaling pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Dual-Action Nucleic Acid Nanoparticles: Innate Immune Activation and Silver Nanocluster-Mediated Targeting of Intracellular Bacteria.ACS nano medicine · 2026Article
- Deep-learning-based virtual screening of antibacterial compounds.Nature biotechnology · 2026Article
- Infectious Spondylodiscitis of Bacterial Causes in Adults: Epidemiology, Pathophysiology, Diagnostic and Treatment Challenges.Microorganisms · 2026Review
- Discovery of HAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Drug screening to identify compounds to eliminateiScience · 2026Article
- Antimicrobial peptides and proteins as rheostats of intestinal homeostasis and immunity.Current opinion in immunology · 2026Review
- Ιdentification of SQ109 analogs with enhanced antimicrobial activity against methicillin-resistantAntimicrobial agents and chemotherapy · 2026Article
- Anticancer, Antitumor, and Antioxidant Microbial Lipids: Mechanism of Action, Production, and Clinical Application.Oxidative medicine and cellular longevity · 2026Review
- Dynamic orchestration of structural and immune cells in acuteFrontiers in immunology · 2026Article
- Janus Microgel Robots for Actively Boosting Catalytic Efficiency and Recovery of Living Materials.Research (Washington, D.C.) · 2026Article
- Antibacterial effect of a dental adhesive containing SCH-79797 onFrontiers in cellular and infection microbiology · 2026Article
- Exploiting Pharmacokinetic/Pharmacodynamic Methods for Optimizing and Accelerating Drug Development of Innovative Anti-Infectives.ChemMedChem · 2026Review
- Discovery of guanidinium salt incorporating cinnamic acid skeleton as new antibacterial agents against Gram-positive bacteria.Frontiers in microbiology · 2026Article
- Biguanide-functionalized peptide mimics effectively combat drug-resistant ESKAPE pathogens and meningitis.Nature communications · 2025Article
- Colistin and Oxyclozanide co-loaded PLGA nano-microspheres to reverse colistin resistance can effectively treat colistin-resistantInternational journal of pharmaceutics: X · 2025Article
93 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
The rise of antibiotic resistance and declining discovery of new antibiotics has created a global health crisis. Of particular concern, no new antibiotic classes have been approved for treating Gram-negative pathogens in decades. Here, we characterize a compound, SCH-79797, that kills both Gram-negative and Gram-positive bacteria through a unique dual-targeting mechanism of action (MoA) with undetectably low resistance frequencies. To characterize its MoA, we combined quantitative imaging, proteomic, genetic, metabolomic, and cell-based assays. This pipeline demonstrates that SCH-79797 has two independent cellular targets, folate metabolism and bacterial membrane integrity, and outperforms combination treatments in killing methicillin-resistant Staphylococcus aureus (MRSA) persisters. Building on the molecular core of SCH-79797, we developed a derivative, Irresistin-16, with increased potency and showed its efficacy against Neisseria gonorrhoeae in a mouse vaginal infection model. This promising antibiotic lead suggests that combining multiple MoAs onto a single chemical scaffold may be an underappreciated approach to targeting challenging bacterial pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.